126 related articles for article (PubMed ID: 38741871)
21. Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Shigeta K; Ishii Y; Hasegawa H; Okabayashi K; Kitagawa Y
World J Surg; 2014 Dec; 38(12):3248-56. PubMed ID: 25167895
[TBL] [Abstract][Full Text] [Related]
22. A Novel
Tong CC; Lam CW; Lam KO; Lee VHF; Luk MY
Front Oncol; 2018; 8():279. PubMed ID: 30087856
[No Abstract] [Full Text] [Related]
23. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
[TBL] [Abstract][Full Text] [Related]
24. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
26. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
[TBL] [Abstract][Full Text] [Related]
27. Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
Leichman CG; Chansky K; Macdonald JS; Doukas MA; Budd GT; Giguere JK; Abbruzzese JL;
Invest New Drugs; 2002 Nov; 20(4):419-24. PubMed ID: 12448660
[TBL] [Abstract][Full Text] [Related]
28. Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
Tsuji T; Sawai T; Takeshita H; Nakagoe T; Hidaka S; Atsushi Nanashima ; Yamaguchi H; Yasutake T; Nagayasu T; Tagawa Y
Cancer Lett; 2004 Feb; 204(1):97-104. PubMed ID: 14744539
[TBL] [Abstract][Full Text] [Related]
29. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
Lin JK; Tan EC; Yang MC
Health Qual Life Outcomes; 2015 May; 13():61. PubMed ID: 25986478
[TBL] [Abstract][Full Text] [Related]
30. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
32. Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.
Merloni F; Ranallo N; Scortichini L; Giampieri R; Berardi R
Cancer Drug Resist; 2019; 2(3):787-802. PubMed ID: 35582578
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
35. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Saif MW; Diasio R
Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
[TBL] [Abstract][Full Text] [Related]
36. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Mercier C; Ciccolini J
Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
[TBL] [Abstract][Full Text] [Related]
37. Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.
Yamashita K; Mikami Y; Ikeda M; Yamamura M; Kubozoe T; Urakami A; Yoshida K; Kimoto M; Tsunoda T
Cancer Lett; 2002 Dec; 188(1-2):231-6. PubMed ID: 12406569
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer.
Brooks GA; Tapp S; Daly AT; Busam JA; Tosteson ANA
Clin Colorectal Cancer; 2022 Sep; 21(3):e189-e195. PubMed ID: 35668003
[TBL] [Abstract][Full Text] [Related]
39. Dihydropyrimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer.
Yu Z; Yang Q; Sun J; Zhen J
Exp Oncol; 2007 Sep; 29(3):192-6. PubMed ID: 18004243
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
